Role of MGMT as biomarker in colorectal cancer

Table 1 Phase 2 clinical trials with alkylating agents in metastatic chemorefractory colorectal cancer

Ref.	Schedule	n(MGMT-m)	RR(MGMT-m)	DCR(MGMT-m)	PFS mo(MGMT-m)	OS mo(MGMT-m)
Amatu et al[21]	DTIC 250 mg/m2 per day, d 1-4 q21d	68 (26)	3% (8%)	12% (44%)	1.7 (NR)1	NR
Hochauser et al[22]	TMZ 150 mg/m2 per day 7 d on/7 d off	372 (37)	3% (3%)	44% (445)	NR	NR
Pietrantonio et al[23]	TMZ 150 mg/m2 per day d 1-5, q28d	323 (32)	12% (12%)	31% (31%)	1.8 (1.8)	8.4 (8.4)
Pietrantonio et al[26]	TMZ 75 mg/m2 per day, d 1-21 q28d	214 (21)	24% (24%)	30% (30%)	2.2 (2.2)	NR

¹Median PFS for MGMT-m patients was not reported, but hazard ratio for progression between methylated and non-methylated patients was 0.66 (95%CI: 0.40-1.10), P = 0.0982;

²The study enrolled 86 patients with MGMT-m metastatic CRC (Mcrc), esophageal, head and neck and non small cell lung cancer; this table reports data of patients with mCRC only;

³Only MGMT-m patients were enrolled in the study;

⁴Preliminary results. DTIC: Dacarbazine; TMZ: Temozolomide; RR: Response rate; DCR: Disease control rate; PFS: Progression-free survival; OS: Overall survival; MGMT-m: MGMT-methylated; NR: Not reported.